



AP31817

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Prell et al.

Serial No.: 09/353,670.

Examiner: Wilson, J.

Filed : July 15, 1999

Group Art Unit: 1623

For : METHODS AND COMPOSITIONS FOR
REGULATING IMIDAZOLINE RECEPTORSINFORMATION DISCLOSURE STATEMENT

I hereby certify that this paper is being deposited with the United States Postal Service as first class mail in an envelope addressed to:
Assistant Commissioner for Patents, Washington, D.C. 20231, on:

January 5, 2003

Date of Deposit

Carmella L. Stephens

Attorney Name

Carmella L. Stephens
Signature41,328

PTO Reg. No.

January 5, 2003

Date of Signature

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 C.F.R. §§1.97 and 1.98, applicant respectfully requests that the documents, listed below and on the accompanying PTO 1449, be considered by the Examiner and made of record in the above-referenced application. Copies of the documents listed are enclosed, with the exception of document number 14, which to date Applicants have not been able to obtain a copy of. Applicants will supply the Examiner with a copy of document number 14 upon its receipt.

1. Tabor and Hayaishi, 1955,
J. American Chem. Soc. 77:505-50611;
2. Karjala SA, 1955,
J. Amer. Chem. Soc. 77:504-505;

3. Karjala SA, 1956,
J. Biol. Chem. 219:9-12;
4. Bauer, 1958, BBA 30:219;
5. Baddiley et al., 1958,
J. Chem Soc. 3743-3745;
6. Bauer, 1962, J. Org. Chem 27:167-170;
7. Crowley GM, 1964,
J. Biol. Chem. 239:2593-2601;
8. Robinson J.D. and Green, 1964,
Nature 203: 1178-1179;
9. Beaven MA et al., 1974,
Europ. J. Pharmacol.
29:138-146;
10. Moss J et al., 1976,
J. Clin Invest 58:137-141;
11. Beaver MA et al., 1976,
Experientia 32:1180-1182;
12. Atlas, D et al. 1987,
J. Cardiovascular Pharmacol.
10 (suppl. 1.12) S122-S127;
13. Atlas D, 1991,
Biochemical Pharmacology
41:1541-1549;
14. Matulic-Adamic, 1991, Korean J.
Med. Chem 1:54-64;
15. Thomas and Prell, 1993,
Soc. Neurosci Abstr 19:85;
16. Li, G et al., 1994, Science 263:966-968;
17. Ernsberger P. et al., 1995,
FASEB J. 9:A114;

18. Thomas and Prell, 1995,
J. Neurochem. 65:818-826;
19. Thomas et al., 1995,
Soc. Neurosci. Abst. 21:1857;
20. Atlas D, 1995,
Annals of the New York Academy of Sciences
763:314-324;
21. Morgan et al., 1995,
Ann. N.Y. Acad. Sci 763:361-373;
22. Regunathan and Reis 1996,
Ann. Dev. Pharmacol Toxicol
36:511-44;
23. Ernsberger P. et al., 1997,
J. Hypertension 15:59-523;
24. Chan et al., 1997,
Brit. J. Pharmacol 120:926-932; and
25. Eglen RM, 1998,
Trends in Pharmacol.Sci;
19:381-390

Identification of the listed documents is not to be construed as an admission of the applicants or attorneys for applicants that such citations are available as "prior art" against the subject application. If the Examiner applies the documents as prior art against any claim in the application and applicants determine that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of the documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should the documents be applied against the claims of the present application.

There should be no fee required for this submission. However, if any fee is required, or if any overpayment has been made, the Commissioner is hereby authorized to charge any fees, or credit or any overpayments made, to Deposit Account 02-4377. A duplicate copy of this paper is enclosed.

Respectfully submitted,



Carmella L. Stephens

Patent Office Reg. No. 41,328

Attorney for Applicants
BakerBotts, LLP
30 Rockefeller Plaza
New York, NY 10112
(212) 408-2500



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1;

of 3

Complete if Known

Application Number 09/353,670

Filing Date 07/15/1999

First Named Inventor Prell

Group Art Unit 1623

Examiner Name Lewis, Patrick

Attorney Docket Number A31817

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	Tabor and Hayaishi, 1955, J. American Chem. Soc. 77:505-50611	
	2	Karjala SA, 1955, J. Amer. Chem. Soc. 77:504-505	
	3	Karjala SA, 1956, J. Biol. Chem. 219:9-12	
	4	Bauer, 1958, BBA 30:219	
	5	Baddiley et al., 1958, J. Chem Soc. 3743-3745	
	6	Bauer, 1962, J. Org. Chem 27:167-170	
	7	Crowley GM, 1964, J. Biol. Chem. 239:2593-2601	
	8	Robinson J.D. and Green, 1964, Nature 203: 1178-1179	
	9	Beaven MA et al., 1974, Europ. J. Pharmacol. 29:138-146	
	10	Moss J et al., 1976, J. Clin Invest 58:137-141	
	11	Beaver MA et al., 1976, Experientia 32:1180-1182	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

† Unique citation designation number. ‡ Applicant is to place a check mark here if English language Translation is attached.



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2

of 3

Complete If Known

Application Number 09/353,670

Filing Date 07/15/1999

First Named Inventor Pr II

Group Art Unit 1623

Examiner Name Lewis, Patrick

Attorney Docket Number A31817

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials [*]	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	12	Atlas, D et al. 1987, J. Cardiovascular Pharmacol. 10 (suppl. 1:12) S122-5127	
	13	Atlas D, 1991, Biochemical Pharmacology 41:1541-1549	
	14	Matulic-Adamic, 1991, Korean J. Med. Chem 1:54-64	
	15	Thomas and Prell, 1993, Soc. Neurosci Abstr 19:85	
	16	Li, G et al., 1994, Science 263:966-968	
	17	Emsberger P. et al., 1995, FASEB J. 9:A114	
	18	Thomas and Prell, 1995, J. Neurochem. 65:818-826	
	19	Thomas et al., 1995, Soc. Neurosci. Abst. 21:1857	
	20	Atlas D, 1995, Annals of the New York Academy of Sciences 763:314-324	
	21	Morgan et al., 1995, Ann. N.Y. Acad. Sci 763:361-373	
	22	Regunathan and Reis 1996, Ann. Dev. Pharmacol Toxicol 36:511-44	

Examiner
Signature


Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.





Substitute for form 14498/PTO

(use as many sheets as necessary)

Sheet 3 of 3

Compl t if Known

Application Number	09/353,670
Filing Date	07/15/1999
First Named Inventor	Prell
Group Art Unit	1623
Examiner Name	Lewis, Patrick
Attorney Docket Number	A31817

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

**Examiner
Signature**

**Date
Considered**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

